http://www.phac-aspc.gc.ca/msds-ftss/msds172e.html(This is only part of the information. More at link)
NAME: Chikungunya virus
SYNONYM OR CROSS REFERENCE: Epidemic polyarthritis and rash, Chikungunya fever, CHIK
CHARACTERISTICS: Togaviridae (formerly group A arboviruses), genus Alphavirus; spherical, enveloped virions 60 nm in diameter, single-stranded, positive-sense RNA genome
SECTION II - HEALTH HAZARD
PATHOGENICITY: Self limiting febrile viral disease; characterized by arthralgia or arthritis typically in the knee, ankle and small joints of the extremities, high fever, followed by a maculopapular rash; buccal and palatal enanthema can occur; nausea and vomiting may occur; mild hemorrhaging may be present especially in children; inapperent infections are common, immunity is long lasting
EPIDEMIOLOGY: Found in Africa, India, south east Asia and the Philippines HOST RANGE: Humans, primates, other mammals, birds INFECTIOUS DOSE: Not known
MODE OF TRANSMISSION: By bite of an infective mosquito
INCUBATION PERIOD: Usually 1-12 days
COMMUNICABILITY: No evidence of person-to-person transmission
SECTION III - DISSEMINATION
RESERVOIR: Most likely primates
ZOONOSIS: Probable - most likely from primates which generate high viremia but manifest no disease
VECTORS: Mosquitoes - Aedes spp.
Ae. aegypti, Ae. africanus
Mansoni spp.
SECTION IV - VIABILITY
DRUG SUSCEPTIBILITY: No antiviral available to dateSUSCEPTIBILITY TO DISINFECTANTS: Sensitive to 70% ethanol, 1% sodium hypochlorite, 2% glutaraldehyde, Sensitive to lipid solvents
PHYSICAL INACTIVATION: Inactivated by moist, dry heat > 58o C; Sensitive to drying
SURVIVAL OUTSIDE HOST: Unknown, less than one day in culture medium at 37o C
SECTION V - MEDICAL
SURVEILLANCE: Monitor for symptoms; confirm by serological analysis and viral isolation in mice or tissue culture
FIRST AID/TREATMENT: Mainly supportive therapy
IMMUNIZATION: None available to date
PROPHYLAXIS: None available